NCT06281665 Treatment With Aspirin After Preeclampsia: TAP Trial
| NCT ID | NCT06281665 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Malamo Countouris |
| Condition | Hypertensive Disorder of Pregnancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-05-29 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2024-05-29 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Eligibility Criteria
Inclusion Criteria: * Postpartum individuals ≥18 years old * Preeclampsia diagnosis Exclusion Criteria: * Fetal anomaly * Multiple gestation * Pre-pregnancy hypertension * Allergy or contraindication to low-dose aspirin * Pre-pregnancy diabetes
Contact & Investigator
Alisse K Hauspurg, MD
PRINCIPAL INVESTIGATOR
UPMC Magee Women's Hospital
Frequently Asked Questions
Who can join the NCT06281665 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Hypertensive Disorder of Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06281665 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06281665 currently recruiting?
Yes, NCT06281665 is actively recruiting participants. Contact the research team at janickia@upmc.edu for enrollment information.
Where is the NCT06281665 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT06281665 clinical trial?
NCT06281665 is sponsored by Malamo Countouris. The principal investigator is Alisse K Hauspurg, MD at UPMC Magee Women's Hospital. The trial plans to enroll 60 participants.